Recent topics related to testosterone deficiency syndrome in Japan

Tsujimura, Akira; Nonomura, Norio

doi:10.1038/aja.2010.132

Cited by 7 publications

(9 citation statements)

References 104 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Most of the studies on LOH have been carried out in Europe, USA and Australia, but there are also studies on the diagnosis, prevalence and treatment of LOH form numerous Asian countries (see e.g. 8 9 10 11 ). Direct comparisons between the studies from different geographic regions are difficult to make because of heterogeneity of experimental approaches, but it is quite likely that the basic features of LOH are very similar in various geographic and cultural environments.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment

2014

View full text Add to dashboard Cite

Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of low T associated with diffuse sexual (e.g., erectile dysfunction), physical (e.g. loss of vigor and frailty) and psychological (e.g., depression) symptoms. This syndrome carries many names, including male menopause or climacterium, andropause and partial androgen deficiency of the ageing male (PADAM). Late-onset hypogonadism (LOH) describes it best and is therefore generally preferred. The decrease of T in LOH is often marginal, and hypogonadism can be either due to primary testicular failure (low T, high luteinizing hormone (LH)) or secondary to a hypothalamic-pituitary failure (low T, low or inappropriately normal LH). The latter form is more common and it is usually associated with overweight/obesity or chronic diseases (e.g., type 2 diabetes mellitus, the metabolic syndrome, cardiovascular and chronic obstructive pulmonary disease, and frailty). A problem with the diagnosis of LOH is that often the symptoms (in 20%–40% of unselected men) and low circulating T (in 20% of men >70 years of age) do not coincide in the same individual. The European Male Ageing Study (EMAS) has recently defined the strict diagnostic criteria for LOH to include the simultaneous presence of reproducibly low serum T (total T <11 nmol l−1 and free T <220 pmol l−1) and three sexual symptoms (erectile dysfunction, and reduced frequency of sexual thoughts and morning erections). By these criteria, only 2% of 40- to 80-year-old men have LOH. In particular obesity, but also impaired general health, are more common causes of low T than chronological age per se. Evidence-based information whether, and how, LOH should be treated is sparse. The most logical approach is lifestyle modification, weight reduction and good treatment of comorbid diseases. T replacement is widely used for the treatment, but evidence-based information about its real benefits and short- and long-term risks, is not yet available. In this review, we will summarize the current concepts and controversies in the pathogenesis, diagnosis and treatment of LOH.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment

2014

View full text Add to dashboard Cite

show abstract

“…Saiko-ka-ryukotsu-borei-to (Saiko) and Kamikihito are types of medicine that are used to treat climacteric symptoms and depression, respectively ( 11 – 14 ), whereas both Unkei-to and AC-Negia are used to treat menstrual irregularity ( 15 , 16 ) (Table 1 ). Saiko-karyuukotsu-borei-to (JAN code.…”

Section: Methodsmentioning

confidence: 99%

Effects of Kamikihito and Unkei-to on Sleep Behavior of Wild Type and Parkinson Model in Drosophila

Ito¹,

Kawasaki²,

Suzuki³

et al. 2017

Front. Psychiatry

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and it is associated with sleep behavior disorders. In Drosophila melanogaster disease model, human α-synuclein A30P overexpressing flies (A30P PD model) have been shown for levy body aggregation and movement disorders. We measured sleep rhythms in the A30P PD model flies using the Drosophila Activity Monitoring system and found that they develop sleep defects at 20 days after eclosion. Furthermore, the total amount of sleep is significantly reduced in middle-aged PD model flies and the reduction has been attributed to nighttime sleep. The number and length of sleep bouts also decreased in middle-aged A30P PD model flies. Feeding of the oriental traditional herbal medicines (Kampo), Kamikihito and Unkei-to significantly ameliorate the level of sleep defects in A30P PD model flies. The Kamikihito and Unkei-to recovered 60-min sleep bouts number in the A30P PD model flies to the level of young (5 days after eclosion) flies. Kamikihito recovered sleep both in wild-type and PD model flies. Unkei-to ameliorates not only sleep but also motor function in PD model flies. The data suggest that Kamikihito and Unkei-to might be useful for the sleep defects in human PD patients as well as healthy human.

show abstract

“…Patients with LOH display reduced sexual desire, dysuria, ED, and urinary frequency. [1][2][3] The main treatment for LOH is TRT. Meanwhile, PDE5 inhibitors, such as sildenafil and tadalafil, are employed extensively for treating ED, 4,5 and daily tadalafil (5 mg) is a primary therapeutic approach for LUTS in patients with BPH in Japan.…”

Section: Introductionmentioning

confidence: 99%

“…Patients with LOH display reduced sexual desire, dysuria, ED, and urinary frequency 1–3 . The main treatment for LOH is TRT.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of testosterone replacement therapy plus alternate‐day tadalafil for patients with late‐onset hypogonadism: An open‐label, randomized, crossover study

et al. 2020

View full text Add to dashboard Cite

To examine the efficacy and safety of combination treatment with testosterone replacement therapy plus alternate-day tadalafil (10 mg) in patients with late-onset hypogonadism. Methods: In this open-label, randomized, crossover study, 29 patients with late-onset hypogonadism were randomly assigned to receive testosterone replacement therapy for 12 weeks followed by combination treatment for 12 weeks (Group 1) or combination treatment for 12 weeks followed by testosterone replacement therapy (Group 2). Symptom questionnaires were administered and blood tests were performed prior to and following each treatment to assess safety and efficacy. At the end of the study, participants were asked about their treatment preferences. Results: An adverse effect, a rheum symptom, occurred in only one participant, and 26 participants completed the study without any toxicity. Scores on the Aging Male Symptoms scale and the modified short version of the International Index of Erectile Function, and Overactive Bladder Symptom Score were significantly improved in the combination treatment phase of Group 2, whereas no significant difference between the phases were observed in Group 1. In total, 12 out of the 14 participants in Group 1 and 11 out of the 12 participants in Group 2 preferred combination treatment, which reached statistical significance (P = 0.008 and 0.004 for Groups 1 and 2, respectively). Conclusions: Testosterone replacement therapy with add-on alternate-day tadalafil is a safe and satisfactory treatment for patients with late-onset hypogonadism.

show abstract

Recent topics related to testosterone deficiency syndrome in Japan

Cited by 7 publications

References 104 publications

Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment

Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment

Effects of Kamikihito and Unkei-to on Sleep Behavior of Wild Type and Parkinson Model in Drosophila

Efficacy of testosterone replacement therapy plus alternate‐day tadalafil for patients with late‐onset hypogonadism: An open‐label, randomized, crossover study

Contact Info

Product

Resources

About